Back to top

Alnylam Expands Into Obesity With New Phase 1 Trial for ALN-6222

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Randomized, Double-blind,...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)